The earnings miss is notable but secondary to the upcoming upLIFT topline data (tumor HI) expected by year-end 2026. The FDA's decision on congenital HI (sunRIZE) remains a binary risk. Monitor for FDA feedback and upLIFT enrollment completion.
Price Chart
Executive Summary
Rezolute reported Q4 FY2026 EPS of -$0.20, a 42.9% miss vs consensus of -$0.14, with no revenue. The miss was driven by higher G&A expenses ($6.7M vs $5.0M a year ago) as the company scales commercial prep for ersodetug. The key catalyst is the upcoming Phase 3 upLIFT topline data for tumor HI expected by end of 2026, which could overshadow the earnings miss.
Key Financial Metrics
Key Facts
- Q4 FY2026 EPS of -$0.20 missed consensus of -$0.14 by 42.9%
- No revenue reported; company is pre-commercial
- Cash and investments $107.8M as of June 30, 2026, down from $167.9M a year ago
- Phase 3 upLIFT study for tumor HI enrolling; topline results expected before end of 2026
- Phase 3 sunRIZE study in congenital HI did not meet primary endpoint; FDA review ongoing with potential need for new trial
- Net loss for Q4 FY2026 was $20.5M, improved from $24.4M a year ago
Financial Impact
EPS miss of 42.9% vs consensus; cash burn of ~$60M in FY2026
Risk Factors
- FDA may require a new randomized trial for congenital HI, limiting ersodetug's commercial potential
- Cash runway of ~$107.8M may not cover multiple failed trials or extended regulatory delays
- Stock-based compensation rising (R&D $6.5M, G&A $8.0M in FY2026) dilutes shareholders
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3368741 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 21, 2026 5d ago | DEF 14A | $3.86 | awaiting T+20 | — | $4.13 (+6.87%) |
Oct 14, 2026 12d ago | 8-K | $3.90 | awaiting T+20 | — | $4.13 (+5.77%) |
Oct 5, 2026 22d ago | 8-K | $4.33 | awaiting T+20 | — | $4.13 (−4.73%) |
Sep 24, 2026 4w ago | 8-K | $3.90 $3.86 | ▲ +1.15% | ▼ −0.32% | $4.13 (−5.77%) |
Sep 24, 2026 4w ago | Press Release | $3.90 $3.86 | ▲ +1.15% | ▼ −0.32% | $4.13 (−5.77%) |
Jul 21, 2026 14w ago | Press Release | $5.09 $4.66 | ▼ −8.45% | ▼ −11.01% | $4.13 (−18.96%) |
Jun 11, 2026 19w ago | Institutional Cluster | $3.86 $5.13 | ▲ +32.90% | ▲ +31.01% | $4.13 (+6.87%) |
Jun 4, 2026 20w ago | Press Release | $4.51 $4.91 | ▲ +8.87% | ▲ +10.24% | $4.13 (−8.54%) |
Jun 2, 2026 21w ago | 8-K | $4.00 $4.95 | ▲ +23.75% | ▲ +25.32% | $4.13 (+3.13%) |
May 12, 2026 23w ago | 8-K | $3.33 $3.86 | ▲ +15.92% | ▲ +16.53% | $4.13 (+23.87%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers